Biogen Ceases Aduhelm Program, Shifts Focus to Leqembi
Biogen is relinquishing its ownership of Aduhelm, the controversial Alzheimer's disease treatment, allowing Neurimmune to regain full rights to the drug. The decision also involves terminating an ongoing clinical trial aimed at demonstrating the treatment's benefits for early-stage Alzheimer's patients. Biogen's CEO emphasized Aduhelm's role in paving the way for new drug development in the field.